{"filing":{"accession_number":"0001193125-26-425553","cik":"0001826892","ticker":"BCAB","company_name":"BioAtla, Inc.","form":"8-K","filing_date":"2026-10-19","report_date":"2026-10-15","primary_document":"bcab-20261015.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1826892/000119312526425553/bcab-20261015.htm"},"events":[{"id":36212,"run_id":33377,"accession_number":"0001193125-26-425553","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"BioAtla entered into a new Standby Equity Purchase Agreement (SEPA) with Yorkville granting the right to sell up to $40 million of common stock over 36 months at 97% of the lowest daily VWAP, and issued 182,110 warrant shares as a commitment fee. The company simultaneously terminated its prior SEPA with Yorkville ($15 million facility), replacing it with this larger dilutive equity financing arrangement that provides on-demand capital access.","company_name":"BioAtla, Inc.","ticker":"BCAB","filing_date":"2026-10-19","form":"8-K","submitted_at":null,"items":[{"id":40539,"accession_number":"0001193125-26-425553","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"BioAtla entered into a Standby Equity Purchase Agreement (SEPA) with Yorkville granting the right to sell up to $40 million of common stock over 36 months, with pricing at 97% of the lowest daily VWAP. The company also issued 182,110 warrant shares as a commitment fee. This is a classic dilutive equity issuance arrangement—a private placement of unregistered securities with a financial intermediary that provides the company access to capital on demand, characteristic of PIPE-like structures. The $40 million commitment amount and warrant issuance represent material dilution to existing shareholders.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-20T10:04:21.752375+00:00","company_name":"","ticker":null,"filing_date":""},{"id":40540,"accession_number":"0001193125-26-425553","item_number":"1.02","item_title":"Termination of a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.72,"reasoning":"The filing discloses termination of a Standby Equity Purchase Agreement (SEPA) with Yorkville that permitted the Company to sell up to $15.0 million of common stock. While Item 1.02 formally addresses the termination, the material substance is the replacement of this equity facility with a new SEPA (referenced in Item 1.01), which represents a material capital-raising arrangement. The prior SEPA had already resulted in 48,092 shares sold for ~$0.4 million, and the new SEPA represents continued reliance on dilutive equity financing—a material event for investors assessing capital structure and shareholder dilution risk.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-20T10:04:21.752375+00:00","company_name":"","ticker":null,"filing_date":""},{"id":40541,"accession_number":"0001193125-26-425553","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Item 3.02 explicitly addresses unregistered sales of equity securities, which is the defining characteristic of dilutive issuances such as private placements or PIPEs. The incorporation by reference to Item 1.01 (a material agreement or transaction item) reinforces that this is a substantive equity capital raise. This type of disclosure is material to investors as it affects ownership dilution and the registrant's capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-20T10:04:21.752375+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":40539,"accession_number":"0001193125-26-425553","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"BioAtla entered into a Standby Equity Purchase Agreement (SEPA) with Yorkville granting the right to sell up to $40 million of common stock over 36 months, with pricing at 97% of the lowest daily VWAP. The company also issued 182,110 warrant shares as a commitment fee. This is a classic dilutive equity issuance arrangement—a private placement of unregistered securities with a financial intermediary that provides the company access to capital on demand, characteristic of PIPE-like structures. The $40 million commitment amount and warrant issuance represent material dilution to existing shareholders.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-20T10:04:21.752375+00:00","company_name":"BioAtla, Inc.","ticker":"BCAB","filing_date":"2026-10-19"},{"id":40540,"accession_number":"0001193125-26-425553","item_number":"1.02","item_title":"Termination of a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.72,"reasoning":"The filing discloses termination of a Standby Equity Purchase Agreement (SEPA) with Yorkville that permitted the Company to sell up to $15.0 million of common stock. While Item 1.02 formally addresses the termination, the material substance is the replacement of this equity facility with a new SEPA (referenced in Item 1.01), which represents a material capital-raising arrangement. The prior SEPA had already resulted in 48,092 shares sold for ~$0.4 million, and the new SEPA represents continued reliance on dilutive equity financing—a material event for investors assessing capital structure and shareholder dilution risk.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-20T10:04:21.752375+00:00","company_name":"BioAtla, Inc.","ticker":"BCAB","filing_date":"2026-10-19"},{"id":40541,"accession_number":"0001193125-26-425553","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Item 3.02 explicitly addresses unregistered sales of equity securities, which is the defining characteristic of dilutive issuances such as private placements or PIPEs. The incorporation by reference to Item 1.01 (a material agreement or transaction item) reinforces that this is a substantive equity capital raise. This type of disclosure is material to investors as it affects ownership dilution and the registrant's capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-20T10:04:21.752375+00:00","company_name":"BioAtla, Inc.","ticker":"BCAB","filing_date":"2026-10-19"}]}